Donor availability and transplantation in CR1
| Characteristics . | No HLA check in CR1 . | HLA check in CR1 (n = 1076) . | |||
|---|---|---|---|---|---|
| Related donor available/HCT+ . | Related donor available/HCT− . | Related donor not available/HCT+ . | Related donor not available/HCT− . | ||
| Total no. of patients | 953 | 243 | 188 | 251 | 394 |
| Cytogenetic risks (SWOG) | |||||
| Favorable, n (%) | 233 (24) | 12 (5) | 47 (25) | 17 (7) | 80 (20) |
| Intermediate, n (%) | 496 (52) | 140 (58) | 84 (45) | 132 (53) | 197 (50) |
| Unfavorable, n (%) | 139 (15) | 52 (21) | 38 (20) | 63 (25) | 69 (18) |
| Unknown, n (%) | 85 (9) | 39 (16) | 19 (10) | 39 (16) | 48 (12) |
| No. of younger patients, n (%) | 257 | 167 | 127 | 175 | 267 |
| Cytogenetic risks | |||||
| Favorable, n (%) | 106 (41) | 8 (5) | 35 (28) | 16 (9) | 60 (22) |
| Intermediate, n (%) | 101 (39) | 97 (58) | 55 (43) | 82 (47) | 125 (47) |
| Unfavorable, n (%) | 30 (12) | 39 (23) | 27 (21) | 49 (28) | 50 (19) |
| Unknown, n (%) | 20 (8) | 23 (14) | 10 (8) | 28 (16) | 32 (12) |
| No. of older patients, n (%) | 696 | 76 | 61 | 76 | 127 |
| Cytogenetic risks | |||||
| Favorable, n (%) | 127 (18) | 4 (5) | 12 (20) | 1 (1) | 20 (16) |
| Intermediate, n (%) | 395 (57) | 43 (57) | 29 (48) | 50 (66) | 72 (57) |
| Unfavorable, n (%) | 109 (16) | 13 (17) | 11 (18) | 14 (18) | 19 (15) |
| Unknown, n (%) | 65 (9) | 16 (21) | 9 (15) | 11 (14) | 16 (13) |
| Characteristics . | No HLA check in CR1 . | HLA check in CR1 (n = 1076) . | |||
|---|---|---|---|---|---|
| Related donor available/HCT+ . | Related donor available/HCT− . | Related donor not available/HCT+ . | Related donor not available/HCT− . | ||
| Total no. of patients | 953 | 243 | 188 | 251 | 394 |
| Cytogenetic risks (SWOG) | |||||
| Favorable, n (%) | 233 (24) | 12 (5) | 47 (25) | 17 (7) | 80 (20) |
| Intermediate, n (%) | 496 (52) | 140 (58) | 84 (45) | 132 (53) | 197 (50) |
| Unfavorable, n (%) | 139 (15) | 52 (21) | 38 (20) | 63 (25) | 69 (18) |
| Unknown, n (%) | 85 (9) | 39 (16) | 19 (10) | 39 (16) | 48 (12) |
| No. of younger patients, n (%) | 257 | 167 | 127 | 175 | 267 |
| Cytogenetic risks | |||||
| Favorable, n (%) | 106 (41) | 8 (5) | 35 (28) | 16 (9) | 60 (22) |
| Intermediate, n (%) | 101 (39) | 97 (58) | 55 (43) | 82 (47) | 125 (47) |
| Unfavorable, n (%) | 30 (12) | 39 (23) | 27 (21) | 49 (28) | 50 (19) |
| Unknown, n (%) | 20 (8) | 23 (14) | 10 (8) | 28 (16) | 32 (12) |
| No. of older patients, n (%) | 696 | 76 | 61 | 76 | 127 |
| Cytogenetic risks | |||||
| Favorable, n (%) | 127 (18) | 4 (5) | 12 (20) | 1 (1) | 20 (16) |
| Intermediate, n (%) | 395 (57) | 43 (57) | 29 (48) | 50 (66) | 72 (57) |
| Unfavorable, n (%) | 109 (16) | 13 (17) | 11 (18) | 14 (18) | 19 (15) |
| Unknown, n (%) | 65 (9) | 16 (21) | 9 (15) | 11 (14) | 16 (13) |
CR1 indicates first complete remission; HLA, human leukocyte antigen; HCT, allogeneic hematopoietic cell transplantation; and SWOG, Southwest Oncology Group.